Clinical Scorecard: Neighborhood Disadvantage and Disparities in Atrial Fibrillation Detection

At a Glance

Key Highlights

• Greater neighborhood disadvantage corresponded to higher odds of AF diagnosis among non-Hispanic White participants and lower odds among non-Hispanic Black participants.
• Non-Hispanic Black participants were disproportionately concentrated in the most disadvantaged neighborhoods.
• Differences in oral anticoagulant prescription fills among participants with diagnosed AF were smaller and less consistent than diagnosis differences.
• Claims-based diagnoses cannot distinguish lower underlying AF incidence from reduced detection.
• The findings do not warrant indiscriminate screening; the article supports equitable diagnostic access and evaluation of targeted strategies.

Guideline-Based Recommendations

Diagnosis

• Current AF guidelines prioritize electrocardiographic confirmation.
• Consider diagnostic access and opportunities for earlier detection, including symptom assessment, primary care referrals, and access to ambulatory monitoring.

Management

• Current AF guidelines prioritize risk-based stroke reduction.
• Align monitoring intensity with risk; the article describes mixed results from randomized screening trials.
• Do not infer equity across the AF care pathway from prescription-fill comparisons limited to people with diagnosed AF.

Monitoring & Follow-up

• Evaluate monitor ordering and completion, specialty referral, and intervals from symptoms to diagnosis and from diagnosis to treatment.
• Assess access to monitoring, follow-up, and cardiology or electrophysiology referral when implementing targeted strategies.

Risks

• Lower rates of clinically recognized AF should not be interpreted as evidence of protection or reduced need for appropriate diagnostic evaluation.
• Pharmacy claims do not confirm medication adherence, and prescription fills alone cannot establish whether treatment is adequate.
• Unequal access to devices, digital or health literacy, follow-up, and referral may limit the equity of mailed patches or wearable-based approaches.

Patient & Prescribing Data

The study included more than 500,000 adults with commercial or Medicare Advantage insurance in the Philadelphia metropolitan area. Treatment analyses were among participants with diagnosed AF.

Oral anticoagulant prescription-fill differences were smaller and less consistent than diagnosis differences. Prescription fills do not confirm adherence, and the study cannot determine whether fill rates were adequate or inadequate.

Clinical Best Practices

• Interpret claims-based AF diagnoses as clinically recognized AF, not as a direct measure of underlying AF burden.
• Assess equitable opportunities for AF recognition as well as treatment after diagnosis.
• Use neighborhood and health-system information to identify diagnostic gaps, as proposed by the article.
• Consider collaboration with community clinics and health care navigators to assist with monitor use and return, transportation, and appointment scheduling.
• Extend research beyond claims-defined diagnosis and include populations not represented or underrepresented in the study.

Related Resources & Content